Immunotherapy and potential molecular targets for the treatment of pituitary adenomas resistant to standard therapy: a critical review of potential therapeutic targets and current developments

Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer

(2017) Vin Yee Chung et al.   GENE

Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model

(2017) Norbert Chauvet et al.   INTERNATIONAL JOURNAL OF CANCER

Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection

(2017) Waseem Touma et al.   JOURNAL OF CLINICAL NEUROSCIENCE

A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis

(2017) Simon Ritchie et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma

(2017) Kristina Y. Aguilera et al.   MOLECULAR CANCER THERAPEUTICS

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis

(2016) S. A. Harrison et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways

(2016) L Zhang et al.   ONCOGENE

PD-L1 expression in human cancers and its association with clinical outcomes

(2016) Jinming Yu et al.   OncoTargets and Therapy

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors

(2016) Yu Mei et al.   Oncotarget

Targeting folate receptor alpha for cancer treatment

(2016) Anthony Cheung et al.   Oncotarget

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: Prognostic biological markers in invasive prolactinomas

(2015) Güliz Demirelli Gültekin et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer

(2015) Jean-Louis Pujol et al.   Journal of Thoracic Oncology

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Hypoxia on DDR1 Expression in Pituitary Adenomas

(2015) Aijun Liu   MEDICAL SCIENCE MONITOR

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas

(2014) Eric Monsalves et al.   ENDOCRINE-RELATED CANCER

The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy

(2014) Youwei Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A Phase I/Ib Study of Folate Immune (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) With Interferon-α and Interleukin-2 in Patients With Renal Cell Carcinoma

(2014) Robert J. Amato et al.   JOURNAL OF IMMUNOTHERAPY

Invasive adenoma and pituitary carcinoma: a SEER database analysis

(2014) Tara M. Hansen et al.   NEUROSURGICAL REVIEW

NRP-1 expression is strongly associated with the progression of pituitary adenomas

(2014) SANG WON LEE et al.   ONCOLOGY REPORTS

Antiproliferative, Antiinvasive, and Proapoptotic Activity of Folate Receptor α-Targeted Liposomal Doxorubicin in Nonfunctional Pituitary Adenoma Cells

(2013) Xiaohai Liu et al.   ENDOCRINOLOGY

A Phase I Study of Folate Immune Therapy (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) in Patients With Renal Cell Carcinoma

(2013) Robert J. Amato et al.   JOURNAL OF IMMUNOTHERAPY

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

(2012) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure of the Discoidin Domain Receptor 1 Extracellular Region Bound to an Inhibitory Fab Fragment Reveals Features Important for Signaling

(2012) Federico Carafoli et al.   STRUCTURE

Microsurgical anatomy of membranous layers of the pituitary gland and the expression of extracellular matrix collagenous proteins

(2011) Savas Ceylan et al.   ACTA NEUROCHIRURGICA

Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha

(2011) Els M. E. Verdegaal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pituitary macroadenoma with persisting dense lymphocytic infiltration in a young male patient

(2011) E. Cakir et al.   CLINICAL NEUROPATHOLOGY

Expression and function of ErbB receptors and ligands in the pituitary

(2011) Odelia Cooper et al.   ENDOCRINE-RELATED CANCER

Differential Expression of Folate Receptor Alpha in Pituitary Adenomas and Its Relationship to Tumor Behavior

(2011) Xiaohai Liu et al.   NEUROSURGERY

Anti-VEGF therapy in pituitary carcinoma

(2011) Leon D. Ortiz et al.   Pituitary

A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice

(2010) N. Demotte et al.   CANCER RESEARCH

VEGF and CD31 Association in Pituitary Adenomas

(2010) Carolina Cristina et al.   ENDOCRINE PATHOLOGY

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)

(2010) K. El-Sahwi et al.   MOLECULAR CANCER THERAPEUTICS

Non-functioning pituitary adenomas

(2009) Yona Greenman et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma

(2009) Sopit Wongkham et al.   CANCER SCIENCE

Epigenetic Control in Pituitary Tumors

(2009) Shereen EZZAT   ENDOCRINE JOURNAL

Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro

(2009) Alexander Gorshtein et al.   ENDOCRINE-RELATED CANCER

Tumor Infiltrating Lymphocytes But Not Serum Pituitary Antibodies Are Associated with Poor Clinical Outcome after Surgery in Patients with Pituitary Adenoma

(2009) Isabella Lupi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Rat Prolactinoma Cell Growth Regulation by Epidermal Growth Factor Receptor Ligands

(2008) G. Vlotides et al.   CANCER RESEARCH

Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia

(2008) X. Zhu et al.   CLINICAL CANCER RESEARCH

Pharmacotherapy for adults with tumors of the central nervous system

(2008) Nina F. Schor   PHARMACOLOGY & THERAPEUTICS